No Data
Hangzhou Minsheng Healthcare Co., Ltd.'s (SZSE:301507) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
People\'s Livelihood and Health: Report for the Third Quarter of 2024
Minsheng Health (301507.SZ): The net income in the first three quarters was 86.1784 million yuan, a year-on-year increase of 5.52%.
Gelonghui, October 28 - Minsheng Health (301507.SZ) released the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.52 billion yuan, a year-on-year increase of 6.98%; the net income attributable to the shareholders of the listed company was 86.1784 million yuan, a year-on-year increase of 5.52%; the net income after deducting non-recurring gains and losses was 82.3756 million yuan, a year-on-year increase of 9.30%; basic earnings per share were 0.24 yuan per share.
Hangzhou Minsheng Healthcare's (SZSE:301507) Returns On Capital Not Reflecting Well On The Business
Minsheng Health (301507.SZ): First-time grant of 3.32 million restricted stocks to incentive recipients.
Gelonghui, September 18th, Minsheng Health (301507.SZ) announced that on September 18, 2024, the company first granted 3.32 million restricted stocks to the participants of the restricted stock incentive plan for the year 2024 at a grant price of 6.67 yuan per share.
Minsheng Health (301507.SZ): BASF (China) as a company's procurement supplier accounts for a relatively low proportion of the total annual procurement amount.
Minsheng Health (301507.SZ) stated on the investor interaction platform on September 12th that the company's raw material procurement, supply, product production, and sales are all normal. The company's products are mostly compound preparations, which generally require multiple raw materials. Fluctuations in the price of a single raw material have little impact on the overall cost of the company's products. BASF (China), as a procurement supplier of the company, accounts for a relatively low proportion of the total annual procurement amount. The company's inventory reserves are also relatively sufficient, and it will not have a significant impact on the company's production, operation, and annual performance.
No Data
